Relationship between the concentration of ergothioneine in plasma and the likelihood of developing pre-eclampsia

Ergothioneine, an antioxidant nutraceutical mainly at present derived from the dietary intake of mushrooms, has been suggested as a preventive for pre-eclampsia. We analysed early pregnancy samples for a cohort of 432 first time mothers as part of the Screening for Endpoints in Pregnancy (SCOPE, European branch) project to determine the concentration of ergothioneine in their plasma. There was a weak association between the ergothioneine levels and maternal age, but none for BMI. Of these 432 women, 97 went on to develop pre-term (23) or term (74) pre-eclampsia. If a threshold was set at the 90th percentile of the reference range in the control population ([≥] 462 ng/mL), only one of these 97 women (1%) developed pre-eclampsia, versus 97/432 (22.5%) whose ergothioneine level was below this threshold. One possible interpretation of these findings, consistent with previous experiments in a reduced uterine perfusion model in rats, is that er-gothioneine may indeed prove protective against pre-eclampsia in humans. An intervention study of some kind now seems warranted.

prevented some of the main symptoms in the rat RUPP model of pre-eclampsia [39]. In 47 view of the above, and its status as a potent antioxidant, it was thus considered plausible 48 to have some utility in the prevention and/or diagnosis of PE in humans [40]. 49 The international Screening for Pregnancy Endpoints (SCOPE) study [25,[41][42][43] 50 (http://scopestudy.net) bio-banked early pregnancy blood samples from a large cohort of 51 first time pregnant women, 4.9% whom developed pre-eclampsia as defined [44] by the 52 International Society of the Study of Hypertension in Pregnancy [41]. Pre-term pre-ec- 53 lampsia was defined as disease necessitating delivery before 27 weeks' gestation. The 54 SCOPE study therefore provided the opportunity to assess whether there was any relation 55 between their levels of ergothioneine and the likelihood of developing early or late-onset 56 pre-eclampsia. The present study reports on a secondary analysis of ergothioneine levels 57 in a previously reported case-control study assessing a panel of metabolite biomarker can-58 didates for pre-eclampsia risk assessment at 15 +/-1 week of gestation [25]. Women with 59 the highest level of ergothioneine had a significantly reduced likelihood of developing 60 either preterm or term pre-eclampsia. One interpretation of such data could be that die- 61 tary supplementation with ergothioneine in pregnancy may reduce pre-eclampsia risk, 62 and this is obviously now worth testing. 63

65
2.1. Overall summary of the cohort studied 66 The nested Case-Control study was defined in the SCOPE -Europe cohort as de-67 scribed fully in [25], and the demographics (  68 work, we leveraged calibration data available in the previous study to estimate the er-69 gothioneine blood levels (ng/mL) in 432 women of whom 335 did not develop PE, 23 suf-70 fered preterm PE, and 74 suffered from term PE. 71 72 In Figure 1 the distribution of ergothioneine levels in the study-subjects are plotted.  The levels range from ~140 ng/ ml to 998 ng/ml, with a median level of ~260 ng/ml. 76 From Figure 1, it is clear that ergothioneine levels are not normally distributed within the 77 study population, but that the long-tailed distribution is skewed to higher concentrations. 78

79
The distribution of ages may be observed in Figure 2, where it may also be seen that 80 there was a weak yet significant correlation of ergothioneine levels with age (r 2 = 0.08; 81 p<0.0001). However, there was no significant relationship (r = -0.07; p=0.14) between er-82 gothioneine levels and BMI ( Figure 3). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; https://doi.org /10.1101/2022.12.19.22283617 doi: medRxiv preprint   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; https://doi.org /10.1101/2022.12.19.22283617 doi: medRxiv preprint

97
A chief finding here is illustrated in Fig 4, where we show the relationship between 98 the levels of ergothioneine and whether the women concerned developed pre-eclampsia, 99 whether at term or pre-term. Taking a threshold of >462 ng/mL, which is equivalent to the 100 90 th percentile in the control population, we see that only 1/74 developed PE at term, and 101 0/23 developed PE pre-term, i.e. only 1/97 (1%) when these numbers are combined devel-102 oped any form of PE. 33/335 (10%) who did not develop PE were also above this threshold. 103 In other words, only a single individual out of 432 examples both had a level of ergothi-104 oneine above 462 ng/mL and developed any form of PE. The ergothioneine levels for those three classes are given in Table 1, where it is clear 107 that without considering the specific distributions in detail the mean and median figures 108 would not have indicated an association between ergothioneine and pre-eclampsia risk. 109 From the distributions as plotted in Fig 4 it can be inferred that within the study popula-110 tion, there is sub-set of study participants who have markedly higher ergothioneine blood 111 levels, giving rise to a bimodal distribution within the study population. 112 The relationship shown in Figure 4 (i.e. setting a cut-off at the 90 th centile) was post-113 hoc, yet it should be evident that a data-driven, machine learning analysis (to be con-114 trasted with a frequentist statistical approach [45,46]) would have discovered it, much as 115 it did [22] in our first foray into pre-eclampsia metabolomics (using a low-resolution mass 116 spectrometer that -as is still common even with high-resolution instruments [47-50] -117 could not identify most peaks of interest). We also note that reference-range-based rules 118 are commonly used in clinical diagnostics to identify a population of interest, whereby 119 patients with blood levels of a marker of interest in e.g. the top or bottom 10% of the ref-120 erence interval are flagged. 121 Using the above 90 th centile as a threshold to identify a population of interest, the 122 following Odds Ratio for developing pre-eclampsia is found in this group; OR = 0.095 123 with 95% Confidence Interval (0.0129 to 0.706) and significance level p<0.02. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; https://doi.org /10.1101/10. /2022 Table 1. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; SCOPE project. Certainly the range of concentrations observed was substantial, from an 145 estimated ~ 140 ng/ml up to 1 µg/ml (Fig 3). Within the study population, the median 146 levels were found to be non-differential between women who developed preterm-, term-147 pre-eclampsia or women who did not develop pre-eclampsia later in pregnancy. How-148 ever, within the women who had ergothioneine levels ≥ the 90 th percentile of the reference 149 population, i.e., women who did not develop pre-eclampsia, only one study participant 150 developed pre-eclampsia. 151 The levels of ergothioneine reflect both intake (especially from mushrooms [60,61]) 152 and the activity of the various ergothioneine transporters [35,36,[62][63][64], and neither of 153 these were either known or controlled. Thus, as with a related study on cardiovascular 154 event incidence, where ergothioneine was strongly (indeed the molecule most strongly) 155 associated with more favourable outcomes in terms of morbidity and mortality [37], this 156 was a purely observational study. Ergothioneine was also the metabolite associated with 157 the lowest hazard ratio for all-cause mortality [65], and had the third highest loading in a 158 signature collection of healthy metabolites [66]. Mushroom consumption is also strongly 159 associated with a lowering of all-cause mortality [67] and of the incidence of mild cogni-160 tive impairment [68]. Consequently, since certain aspects of the pre-eclampsia syndrome 161 share hallmarks of vascular disease [69][70][71], this study adds weight to the idea that it might 162 be a useful nutraceutical in the prevention of (cardio)vascular diseases more generally. 163

164
Ergothioneine was one of the compounds analysed with multiplex targeted liquid chro-165 matography -tandem mass spectrometry assay for pre-eclampsia biomarker candidates 166 as detailed in [25]. In the latter study, biomarker levels were expressed as relative concen-167 trations whereby for any sample the target metabolite read-out was divided by the read-168 out as obtained from a stable-isotope labelled metabolite internal standard spiked in equal 169 amounts across all samples. Deuterated ergothioneine (D9) served as the stable-isotope 170 labelled metabolite internal standard for ergothioneine quantification. 171 For this secondary data analysis, the relative ergothioneine concentrations were converted 172 in estimated blood levels (ng/ml) using the calibrators co-analysed with the patient sam-173 ples [25]. 174 In brief, calibration curves were generated by means of firstly fortifying a pooled 175 plasma (Technopath plasma with 2% K2-EDTA anticoagulant Lot PF-05171, Technopath, 176 Ireland) with the metabolites of interest and then serially diluting the fortified sample 177 with PBS/BSA buffer (0.01M phosphate buffer and 0.5% Albumin). The metabolites levels 178 for the fortified matrix as well as the concentration span were estimated based on prelim-179 inary evaluations. This led to the creation of an 8-point calibration curve for all metabolites 180 spanning a ~20-fold dynamic range. (CAL1; relative level = 100 to CAL8, relative level = 181 5.83). In a separate experiment the levels of ergothioneine in the pooled plasma were de-182 termined by means of standard addition [72], yielding an estimated level of 138 ng/ml. 183 Using this information, the ergothioneine calibration range expressed in ng/mL is easily 184 derived (174 ng/ml (CAL8) -752 ng/ml (CAL1)). It is noted that said calibration range 185 covers 93.5% of all patient samples assessed; moreover, we typically find that the linear 186 range extends beyond the set calibration range for the metabolites assessed. Verification 187 that the ergothioneine calibrator curves effectively mitigated technical variability fol-188 lowed the estimation of imprecision from the analysis of 73 duplicate patient samples (in-189 dependently prepared and randomly distributed across study batches) using the method 190 of Hyslop and White [73], returning a satisfactory Coefficient of Variation (%) = 11. 5%. 191 Conclusions 192 The very striking observation that, in this cohort, only 1 individual out of 97 (1%) 193 women with an ergothioneine level above 462 ng/ml manifested pre-eclampsia, whereas 194 in the total cohort 97/432 (22.5%) did, demands an explanation. The easiest one is that this 195 molecule is significantly protective towards (and may be consumed during) the 196 . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; development of pre-eclampsia. It is worth noting that, as well as its occurrence in all 197 known culinary mushrooms, ergothioneine is an available nutritional supplement, whose 198 safety has been well established [51,[74][75][76][77]. Such an analysis will best be done via a ran-199 domized controlled trial. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; https://doi.org /10.1101/10. /2022  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; https://doi.org /10.1101/10. /2022  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 20, 2022. ; https://doi.org /10.1101/10. /2022